Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
Van Kuijk AWR, Nurmohamed MT, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Sharaf M, Noël W, Theander E, Smolen JS, Gossec L, van der Horst-Bruinsma IE. Van Kuijk AWR, et al. Among authors: noel w. Rheumatology (Oxford). 2023 Oct 3;62(10):3382-3390. doi: 10.1093/rheumatology/kead089. Rheumatology (Oxford). 2023. PMID: 36810788 Free PMC article.
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Sharaf M, Theander E, Smolen JS. Gossec L, et al. Among authors: noel w. Ann Rheum Dis. 2023 Apr;82(4):496-506. doi: 10.1136/ard-2022-222879. Epub 2022 Dec 13. Ann Rheum Dis. 2023. PMID: 36600178 Free PMC article.
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA.
Richette P, Vis M, Ohrndorf S, Tillett W, Ramírez J, Neuhold M, van Speybroeck M, Theander E, Noel W, Zimmermann M, Shawi M, Kollmeier A, Zabotti A. Richette P, et al. Among authors: noel w. RMD Open. 2023 Mar;9(1):e002934. doi: 10.1136/rmdopen-2022-002934. RMD Open. 2023. PMID: 37001920 Free PMC article. Clinical Trial.
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Sharaf M, Theander E, Smolen JS. Gossec L, et al. Among authors: noel w. Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y. Arthritis Res Ther. 2023. PMID: 37353788 Free PMC article.
Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort.
Gremese E, Ciccia F, Selmi C, Cuomo G, Foti R, Matucci-Cerinic M, Conti F, Fusaro E, Guggino G, Iannone F, Delle Sedie A, Perricone R, Idolazzi L, Moscato P, Theander E, Noël W, Bergmans P, Marelli S, Gossec L, Smolen JS; Italian PsABio study. Gremese E, et al. Among authors: noel w. Clin Exp Rheumatol. 2023 Mar;41(3):735-743. doi: 10.55563/clinexprheumatol/j33pjt. Epub 2022 Oct 12. Clin Exp Rheumatol. 2023. PMID: 36226614 Free article.
72 results